If you want to understand biological aging at the cellular level, the mitochondria are the right place to start. These organelles are the primary sites of ATP production — the energy currency that powers virtually every cellular process. And the research literature is unambiguous that mitochondrial function declines with age: ATP production decreases, reactive oxygen species accumulate, mitochondrial membrane integrity degrades, and the quality control mechanisms that normally clear damaged mitochondria (mitophagy) become less effective.
The downstream consequences of this mitochondrial dysfunction are visible across the body: reduced cellular energy availability, increased oxidative stress, impaired DNA repair, and accelerated tissue aging in every organ system that depends on high mitochondrial output — which is most of them.
The research question that wellness and longevity clinics are increasingly focused on: what interventions address mitochondrial dysfunction specifically, through mechanisms that go beyond general antioxidant support or caloric restriction? SS-31 and NAD+ represent the most research-grounded answers currently available.
Free Peptide Research Guide 2026/2027
Download our comprehensive research guide — evidence-based peptide science insights for healthcare practitioners and researchers.
NAD+: The Coenzyme at the Center of Cellular Energy Metabolism
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell, where it functions as a critical electron carrier in the metabolic pathways that produce ATP. But its role in aging biology extends well beyond energy metabolism: NAD+ is also an essential cofactor for sirtuins (the protein family most associated with longevity research) and for PARP enzymes involved in DNA repair.
The research on NAD+ and aging starts with a consistent finding across multiple species and tissue types: NAD+ levels decline with age. Intracellular NAD+ in humans is estimated to decline by roughly 50% between young adulthood and middle age, with continued decline thereafter. This decline correlates with the mitochondrial dysfunction, reduced sirtuin activity, and impaired DNA repair capacity that characterize cellular aging.
The research on NAD+ precursors — primarily NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — has investigated whether restoring NAD+ levels in aging tissues can reverse or slow these aging-associated changes. Preclinical studies in animal models have shown meaningful effects on mitochondrial function, muscle performance, metabolic health, and longevity parameters. Human clinical data is developing rapidly, with multiple trials now published examining NAD+ precursor supplementation in aging populations.
For wellness clinics, NAD+ is the longevity compound with the deepest research foundation and the broadest client accessibility — the compound whose mechanism most clients can understand intuitively, and whose research rationale translates most directly from the published literature to the client conversation.
Available through Hello Stacks for research use only.
SS-31: Mitochondrial Membrane Targeting
SS-31 (Elamipretide) addresses mitochondrial aging through a more specific and more recently characterized mechanism: direct targeting of the inner mitochondrial membrane.
The compound is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) designed to selectively concentrate in the inner mitochondrial membrane, where it interacts with cardiolipin — a phospholipid that is uniquely present in the inner mitochondrial membrane and essential for maintaining the structure and function of the electron transport chain complexes that produce ATP.
With age, cardiolipin undergoes oxidative modification that disrupts its interaction with the electron transport chain complexes, reducing ATP synthase efficiency, increasing electron leak (which produces reactive oxygen species), and contributing to the mitochondrial dysfunction that characterizes aging at the cellular level. SS-31’s proposed mechanism is to stabilize the cardiolipin-electron transport chain interaction — essentially shoring up the structural foundation of mitochondrial energy production at the molecular level.
The preclinical research on SS-31 is substantial: published animal studies have examined its effects on cardiac function, kidney disease, muscle atrophy, neurological aging, and ischemia-reperfusion injury — contexts where mitochondrial dysfunction is a central driver of pathology. In aged animal models, SS-31 administration has been associated with restoration of mitochondrial function, improved tissue energetics, and protection against oxidative damage.
The human clinical research on SS-31 is less developed than the preclinical literature, but Elamipretide is in active clinical development for heart failure (where mitochondrial dysfunction in cardiomyocytes is well-established), with trials providing human safety data and early efficacy signals.
Available through Hello Stacks for research use only.
The Research Rationale for Combining SS-31 and NAD+
SS-31 and NAD+ address mitochondrial aging through different but complementary mechanisms:
NAD+ addresses the substrate availability problem — the decline in the coenzyme that sirtuins require for mitochondrial quality control (through SIRT1 and SIRT3) and that the cell requires for DNA repair and energy metabolism. Restoring NAD+ levels gives the cell more of the raw material these systems need to function.
SS-31 addresses the structural problem — the inner membrane degradation that reduces the efficiency of ATP production regardless of substrate availability. Even with adequate NAD+, a compromised electron transport chain produces less ATP and more reactive oxygen species than a structurally sound one.
The combination hypothesis is that addressing both the substrate and the structure produces more comprehensive mitochondrial support than either alone. This remains an area of preclinical investigation rather than established clinical practice. But the non-overlapping mechanisms provide a clear scientific rationale for studying the combination.
What This Means for Wellness Clinic Protocol Design
The SS-31 + NAD+ stack represents the premium tier of a longevity and anti-aging research offering — the deepest mechanistic conversation available for clients who’ve moved past surface-level wellness into serious engagement with the biology of aging.
The standard NAD+ offering remains the accessible entry point: a compound with extensive published research, an understandable mechanism (cellular energy), and a client base that’s already familiar with NAD+ IV drips and precursor supplementation from the broader wellness market. The research conversation here is about mechanism depth — what NAD+ actually does at the mitochondrial level, why it declines with age, and what the research on precursor supplementation shows.
SS-31 extends that conversation into territory most competitors haven’t reached. The cardiolipin mechanism, the electron transport chain, the inner membrane structure — this is a research discussion that requires real compound knowledge to have credibly. Practices that can have it are working with a different kind of client: the researcher-minded longevity client who’s already read David Sinclair, has an established supplement protocol, and is looking for a practice that can meet them at the frontier of what the peer-reviewed literature supports.
That client doesn’t comparison-shop on price. They comparison-shop on depth.
Want to discuss building a mitochondrial longevity research tier for your wellness practice? Reach out to Ted at 725.275.7267 | hellostacks.com | stackone.com
All compounds referenced are for research use only. Not FDA-approved for any clinical application. Nothing here constitutes medical or clinical advice. Consult qualified professionals before implementing any protocol in a clinical setting.